Notice: Get a jump on 2015 — Pay your 2015 ASA membership dues now!

>

MEETINGS / EVENTS

RSS

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit

>

FDA MEDWATCH ALERTS

December 18, 2014

0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter: Recall - Particulate Matter

Summary:

FDA MedWatch Recall - Particulate Matter

November 21, 2014

FDA MedWatch - Respironics California, Esprit V1000 and V200 Ventilators: Class I Recall - Power Failure May Occur

Summary:

FDA MedWatch Respironics California Esprit V1000 and V200 Ventilators Class I Recall

November 21, 2014

FDA MedWatch - Highly Concentrated Potassium Chloride Injection, 10 mEq per 100 mL by Baxter: Recall - Mislabeled

Summary:

Highly Concentrated Potassium Chloride Injection 10 mEq per 100 mL by Baxter Recall Mislabeled

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

U.S. Senate Committee Advances Compounding Pharmacy Oversight Bill

Thursday, May 23, 2013

On May 22, the Senate Health, Education, Labor and Pensions (HELP) Committee passed the Pharmaceutical Compounding Quality and Accountability Act (S. 959) by a voice vote. 

This bill establishes a boundary between traditional pharmacy compounding and a new category of businesses called "compounding manufacturers," which are defined as facilities that: 1) make sterile products without a prescription and sell those products across state lines, or 2) repackage preservative free sterile products.  If enacted, the bill provides that compounding manufacturers would be subject to a federal, uniform set of rules while traditional pharmacies would continue to be regulated by states.  Of particular interest to anesthesiologists, the legislation specifically permits compounding manufacturers to make drugs that are in shortage. 

The FDA has sought greater oversight of compounding pharmacies since the meningitis outbreak last fall.  As of May 23, the CDC has reported 741 cases of fungal meningitis and 55 deaths.

The bill now awaits consideration by the full U.S. Senate.  The U.S. House of Representative has not yet drafted a compounding bill, but the House Committee on Energy and Commerce’s Subcommittee on Health held a hearing covering the compounding issue. 

ASA will continue to review and monitor this bill to ensure that it addresses our concerns with patient safety and anesthesiologists' ability to access the medications they need.

Read the Senate HELP Committee summary of the bill.

« Back to Washington Alerts